Laura Elizabeth Lansdowne
Managing Editor
As managing editor, Laura works closely with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She plays an active part in the general oversight and training of the in-house editorial team, as well as working directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.
Latest Content
Industry Insight
Shielding Oncolytic Viruses From the Immune System To Improve Cancer Treatment
While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.
Podcast
Opinionated Science Episode 42: Caffeine for ADHD and Cancer-Sniffing Worms
In this episode of Opinionated Science, the team discusses a new advance that uses a microscopic worm to sniff out lung cancer, why caffeine is being investigated to treat ADHD and a stats study that may undermine an important area of neuroscience.
Industry Insight
Live Biotherapeutics ‒ A Novel Way To Treat Disease
The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).
Article
Applying Organ-on-a-Chip Tech to the Lymphatic System
Texas A&M University's Dr. Abhishek Jain and colleagues have developed the first lymphangion-chip to model the functional unit of a lymph vessel. The hope is that the chip will allow researchers to gain a clearer picture of the mechanical forces controlling lymphatic physiology and pathophysiology, which in turn will help to identify new therapeutic targets for conditions such as lymphedema.
News
Artificial Sweeteners Are Associated With Increased Cancer Risk, Finds Large-Scale Cohort Study
Results from a large cohort study of >100,000 French adults suggest that some artificial sweeteners found in foods and beverages are associated with an increased risk of cancer. The findings were published in PLOS Medicine.
Infographic
Tumor Biology
Download this infographic to explore cancer cell physiology, the composition of the tumor microenvironment and mechanisms regulating tumor initiation and cancer progression.
Article
What Role Do Bitter Taste Receptors Play in Cancer?
To determine the current state of knowledge on the role of bitter taste receptors in cancer, researchers analyzed extensive data gathered using PubMed and Google Scholar. Technology Networks recently had the pleasure of speaking with two of the study’s authors, Dr. Agnes Mistlberger-Reiner and Sofie Zehentner to learn more about their findings.
Industry Insight
Leveraging the T-Cell Response to Epstein-Barr Virus To Treat Life-Threatening Diseases
Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.
Podcast
Opinionated Science Episode 40: A Herpes-MS Link, mRNA Pills and Regenerating Frog Limbs
In the latest Opinionated Science, the first of 2022, the TN team discusses why multiple sclerosis links to a herpesvirus, a limb regenerating Fitbit that has amputee frogs hopping again and the next era of pill-based mRNA technology.
Article
Harnessing the Immune System To Treat Cancer
In this article, we consider some of the work being done to enhance the T-cell response to tumors, discuss the promise of oncolytic virotherapy and highlight the potential benefits of combined therapy.
Advertisement
